Nuclear Medicine

Doç. Dr. Sevda Sağlampınar Karyağar

Thyroid NeoplasmsColorectal NeoplasmsSkin NeoplasmsAdenocarcinomaCarcinoma, Non-Small-Cell Lung

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which diseases does this doctor work on?

From source
  • Thyroid Neoplasms 3 publications
    Source: OpenAlex / PubMed MeSHView publications
  • Colorectal Neoplasms 2 publications
  • Skin Neoplasms 2 publications
  • Adenocarcinoma 2 publications
  • Carcinoma, Non-Small-Cell Lung 2 publications

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • SpecialtyNuclear Medicinesaglik.gov.trFrom source
  • Institutionİstanbul Prof. Dr. Cemil Taşcıoğlu Şehir Hastanesisaglik.gov.trFrom source
  • Area of workThyroid NeoplasmsExtracted from 3 publications · Model version —From source
  • Publications33 publicationsOpenAlex, Europe PMC, ORCIDFrom source
  • ORCID0000-0002-6356-8280ORCIDFrom source
  • Last synchronised5 November 2026 08:55https://cemiltascioglush.saglik.gov.tr/TR-1563433/doktorlarimiz.html#sevda-saglampinar-karyagarsaglik.gov.tr

Scientific work

Publications on Thyroid Neoplasms

33 publications
  1. Malignant Phosphaturic Mesenchymal Tumor With Lung Metastasis

    Cureus, 2026

    DOI 10.7759/cureus.102504 PMID 41769508 Open-access full textSource: OpenAlex

  2. Comparison of Radioactive Iodine Activities in Terms of Short- and Long-term Results in Ablation Therapy in Patients with Low-risk Differentiated Thyroid Cancer

    Molecular imaging and radionuclide therapy, 2023

    DOI 10.4274/mirt.galenos.2022.05826 PMID 37337764 4 citations (Europe PMC) Open-access full textSource: Europe PMC

  3. Contribution of Lower Extremity 68Ga PSMA PET/CT Imaging to Diagnosis and Treatment in Prostate Cancer

    European Archives of Medical Research, 2022

    DOI 10.4274/eamr.galenos.2021.50251 Open-access full textSource: OpenAlex

  4. The Predictive Value of Baseline Volumetric PET/CT Parameters on Treatment Response and Prognosis in Locally Advanced Rectal Cancer Treated with Neoadjuvant Chemoradiotherapy

    Journal of Gastrointestinal Cancer, 2021

    DOI 10.1007/s12029-021-00608-y PMID 33651265 11 citations (Europe PMC) Open-access full textSource: OpenAlex

  5. Can 68Ga-PSMA PET/CT-derived prostate-specific membrane antigen expression parameters predict prostate-specific antigen response to enzalutamide treatment?

    Nuclear Medicine Communications, 2021

    DOI 10.1097/mnm.0000000000001431 PMID 33958536 7 citations (Europe PMC) Source: ORCID

  6. Thyroid Cancer Prevalence and Risk in Incidental Thyroid Lesions Detected with 18F-FDG PET/CT

    European Archives of Medical Research, 2021

    DOI 10.4274/eamr.galenos.2020.94803 Open-access full textSource: OpenAlex

  7. The relationship between pre-treatment 18F-FDG PET/CT metabolic data and treatment response in patients with cervix uteri cancer.

    PubMed, 2021

    DOI 10.1967/s002449912302 PMID 33866335 2 citations (OpenAlex) Source: OpenAlex

  8. Bone Metastases on 18F-FDG PET/CT Imaging in Patients with Colorectal Cancer. Does Bone Scintigraphy Still Have a Role?

    Eurasian Journal of Medical Investigation, 2021

    DOI 10.14744/ejmi.2021.86631 Source: OpenAlex

  9. The predictive role of metabolic tumor volume on no response to neoadjuvant chemotherapy in patients with breast cancer

    Journal of Oncology Pharmacy Practice, 2020

    DOI 10.1177/1078155219898504 PMID 31955700 3 citations (Europe PMC) Source: OpenAlex

  10. The correlation between tumor markers and Ga-68 DOTA-TATE PET/CT findings in patients with advanced medullary thyroid cancer

    Revista Española de Medicina Nuclear e Imagen Molecular (English Edition), 2020

    DOI 10.1016/j.remnie.2020.04.005 PMID 33451923 1 citation (Europe PMC) Open-access full textSource: OpenAlex

View all 33 publications